The ongoing healthcare public offers have been fully subscribed on the second day of the three-day bid period. The ₹630-crore Dr Lal PathLabs public issue has been subscribed 2.64 times, according to data provided by the stock exchanges at 5 p.m. on Wednesday.
The QIB portion was subscribed 6.12 times and retail 1.55 times. Meanwhile, the ₹1,344-crore Alkem Laboratories public offer received total subscription of 1.41 times. Qualified institutional buyers bid for 2.33 times of the shares set apart for them, HNIs 0.64 times and retail investors 1.27 times.